These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15072549)

  • 1. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
    Arlt W; Neogi P; Gross C; Miller WL
    J Mol Endocrinol; 2004 Apr; 32(2):425-36. PubMed ID: 15072549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.
    Arlt W; Auchus RJ; Miller WL
    J Biol Chem; 2001 May; 276(20):16767-71. PubMed ID: 11278997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
    Ming Y; Hu X; Song Y; Liu Z; Li J; Gao R; Zhang Y; Mei H; Guo T; Xiao L; Wang B; Wu C; Xiao X
    PLoS One; 2014; 9(7):e102102. PubMed ID: 25004107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
    Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
    Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.
    Kempná P; Hofer G; Mullis PE; Flück CE
    Mol Pharmacol; 2007 Mar; 71(3):787-98. PubMed ID: 17138841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.
    Milton FA; Cvoro A; Amato AA; Sieglaff DH; Filgueira CS; Arumanayagam AS; de Lima Mdo C; Pitta IR; de Assis Rocha Neves F; Webb P
    Biochem Biophys Res Commun; 2015 Aug; 464(3):718-23. PubMed ID: 26168725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
    Berger J; Tanen M; Elbrecht A; Hermanowski-Vosatka A; Moller DE; Wright SD; Thieringer R
    J Biol Chem; 2001 Apr; 276(16):12629-35. PubMed ID: 11278270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
    Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
    J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents.
    Neogi P; Lakner FJ; Medicherla S; Cheng J; Dey D; Gowri M; Nag B; Sharma SD; Pickford LB; Gross C
    Bioorg Med Chem; 2003 Sep; 11(18):4059-67. PubMed ID: 12927868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
    Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
    J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2.
    Flück CE; Yaworsky DC; Miller WL
    Epilepsia; 2005 Mar; 46(3):444-8. PubMed ID: 15730543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
    Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
    Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.